Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib + zimberelimab + nab-paclitaxel in advanced triple-negative breast cancer
ChiCTR2300071563Phase 2Recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- May 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of surufatinib, zimberelimab and paclitaxel in triple-negative breast cancer (TNBC), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoint: progression-free survival. Started May 2023; status: recruiting.
02
Drugs
surufatinibzimberelimabpaclitaxel
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2300071563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071563.